COMBINATION THERAPY INCLUDING A KRAS G12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS
申请人:Amgen Inc.
公开号:US20200222407A1
公开(公告)日:2020-07-16
The present invention provides combination therapy that includes an KRAS
G12C
inhibitor, such as
or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRAS
G12C
inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.